Chester County News and Community Website
WILMINGTON, DE — AstraZeneca’s TAGRISSO combined with savolitinib extended median survival by nearly five months compared with chemotherapy in a Phase III trial involving patients with EGFR-mutated non-small cell lung …
AstraZeneca Drug Combination Extends Lung Cancer Survival Read More WILMINGTON, DE — AstraZeneca’s IMFINZI combined with Amgen’s tarlatamab-dlle extended median survival to 21.1 months in patients with extensive-stage small cell lung cancer, compared with 12.7 months for IMFINZI alone, …
AstraZeneca Drug Combination Extends Lung Cancer Survival Read More WILMINGTON, DE — AstraZeneca has launched ZEGFROVY (sunvozertinib) in the United States for adults with a specific form of advanced lung cancer that has progressed following platinum-based chemotherapy, expanding access …
AstraZeneca Launches Targeted Lung Cancer Drug in U.S. Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a 68% tumor response rate and median progression-free survival of 16 months at the higher dose of its experimental lung …
ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) said its experimental lung cancer drug firmonertinib failed to significantly improve progression-free survival compared with chemotherapy in a pivotal Phase 3 …
ArriVent’s Lung Cancer Drug Fails Key Phase 3 Trial Endpoint Read More
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. secured a $3.17 million, five-year National Cancer Institute grant to advance an experimental radiopharmaceutical toward potential clinical testing in patients with non-small …
MTTI Lands $3.17 Million NCI Grant to Advance Lung Cancer Drug Read More
WASHINGTON, D.C. — U.S. cancer death rates declined for both men and women from 2019 through 2023, extending a more than two-decade drop driven largely by faster progress against lung …
Lung Cancer Gains Push U.S. Cancer Death Rates Lower Read More WILMINGTON, DE — AstraZeneca (NYSE: AZN) and Daiichi Sankyo’s Enhertu extended median progression-free survival by six months versus pembrolizumab plus chemotherapy in a Phase III trial of first-line treatment for …
Enhertu Extends PFS by Six Months in HER2 Lung Cancer Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) Tagrisso showed a sustained survival benefit eight years after treatment in a Phase III trial of patients with early-stage EGFR-mutated non-small cell lung cancer, …
Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial Read More WILMINGTON, DE — AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of first-line extensive-stage small cell lung cancer, potentially expanding treatment options for …
AstraZeneca Lung Cancer Combo Extends Survival in Phase III Read More